Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WoundStat is a topical hemostatic agent composed of granular smectite, a mineral-based compound. Developed by researchers at Virginia Commonwealth University and manufactured by TraumaCure Inc., it is classified as a medical device rather than a pharmaceutical drug. The mechanism of action involves the rapid absorption of water from blood to form a malleable clay-like material with high tissue adhesiveness, while the anionic surface of the smectite granules activates the intrinsic coagulation pathway to accelerate clot formation. It was primarily indicated for the temporary control of severe external hemorrhage in traumatic or battlefield settings, particularly where tourniquets are impractical. However, its use was suspended by the U.S. military in 2008 following reports of potential vascular injury and thrombosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on WoundStat.